Apimeds amends settlement to restructure board; appoints Chae director

Apimeds Pharmaceuticals US, Inc.

On Sep 10, 2026, company amended settlement with Inscobee Parties, altering Board structure.
Interim Board set to only Kogan, O'Donnell, Weintraub, and Chae; no removals without Menon/Inscobee consent.
Post-conversion Board: 4 MindWave-nominated independents, 2 Menon nominees (incl. Menon), and Chae.
Sungjoon Chae appointed to Board effective Sep 10, 2026; already Co-CEO since May 2026.
Agreement is Delaware-governed; full text filed as Exhibit 10.1.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sungjoon Chae

member of the Board

APUS · Apimeds Pharmaceuticals US, Inc.

Effective: 2026-09-10
Filed: September 11, 2026, 9:10 AM ET

the Board appointed Sungjoon Chae to serve as a member of the Board, effective as of such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sungjoon Chae was appointed as member of the Board at Apimeds Pharmaceuticals US, Inc..

Action: appointed
Role: member of the Board

Exact text from the filing

the Board appointed Sungjoon Chae to serve as a member of the Board, effective as of such date.

View on SEC.gov

Apimeds Pharmaceuticals US, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-099002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.